Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $ 74 billion Celgene deal agreement. And an activist may be joining that list. Known agitator Starboard Value has taken a stake in the New Jersey drugmaker, Bloomberg’s sources say, though the size of that stake and the hedge fund’s plans are still unclear. A… Read More »
GlaxoSmithKline has been working to unload its Indian consumer products business, including the nutritional beverage Horlicks, and now the company may be almost there. Following a monthslong bidding process that in October reportedly centered on potential buyers Nestlé, Coca-Cola and Unilever, Unilever is now the leading bidder, Reuters reports. While the Financial Times reported on Tuesday that the… Read More »
Critics of Takeda’s $ 62 billion Shire buyout and Shire’s own investors have fretted lately about the company’s standing in the hemophilia market. But immunology is a different story. In the third quarter, the unit continued to post “strong growth,” as Jefferies analyst David Steinberg put it in a Thursday note to clients, with revenues… Read More »